Navigation Links
ADMIRE-HF Clinical Trial Published in the Journal of the American College of Cardiology
Date:5/17/2010

d provides data that clinicians may be able to use to improve current practice."

ADMIRE-HF Results

The evaluable efficacy population consisted of 961 patients.  During the median follow-up period of 17 months, first cardiac events were observed in 237 patients (25%); these included 163 cases of heart failure progression, 50 arrhythmic events, and 24 cardiac deaths.  The risk of cardiac events (the trial's primary endpoint) was significantly lower for patients with an H/M greater than or equal to 1.60, with a hazard ratio (HR) of 0.40 (97.5% confidence interval [CI]: 0.25 to 0.64; p < 0.001). A Cox proportional hazards analysis based on a continuous numerical H/M (i.e., rather than on separating patients according to H/M greater than or equal to 1.60 or <1.60) revealed an even lower HR of 0.22 (97.5% CI: 0.10 to 0.47; p < 0.001).(1)

Survival analysis revealed two-year event rates of 15% for patients with an H/M greater than or equal to 1.60, compared to 38% for patients whose H/M was below 1.60. Hazard ratios for individual events, based on an H/M threshold of 1.60, were as follows: heart failure progression, 0.49 (95% CI: 0.32 to 0.77; p = 0.002); arrhythmic events, 0.37 (95% CI: 0.16 to 0.85; p = 0.37); and cardiac death, 0.14 (95% CI: 0.03 to 0.58; p = 0.006).(1)

A multivariate analysis of the pooled ADMIRE-HF data using only the planar 123I-mIBG imaging results produced a model with four independent variables contributing to the prediction of the primary outcome events: late H/M, left ventricular ejection fraction (LVEF), NYHA functional class, and plasma B-type brain natriuretic peptide (BNP).(1)

In subanalyses, the H/M provided significant information to complement BNP – a frequently used marker of prognosis in heart failure patients – for identifying patien
'/>"/>

SOURCE GE Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
2. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
3. 3M and CitiusTech to Integrate 3M Healthcare Data Dictionary With CitiusTechs BI-Clinical Healthcare Business Intelligence Framework
4. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
5. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
6. Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
7. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
8. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
9. US HIFU Receives Unanimous Approval to Continue the Clinical Investigation of High Intensity Focused Ultrasound (HIFU) for Treatment of Prostate Cancer
10. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
11. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Rock Creek Pharmaceuticals, Inc. (NASDAQ: ... announced that the Food and Drug Administration ("FDA"), has ... on RCP,s Investigational New Drug ("IND") application before granting ... the US. Dr. Chris Chapman , ... comments on our IND. When we receive the agency,s ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... GREEN BAY, Wis., Sept. 16 Top researchers at ... Center in Dallas are exploring the clinical applications of ... potency, and bioavailability. Previous studies have ... than other forms of curcumin, and had a retention ...
... Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic... -- REGENSBURG, Germany, September ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
Cached Medicine Technology:BCM-95 Demonstrates Superior Anti-Inflammatory Effects 2Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 2Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 3Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 4Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 5Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 6Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 7Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 8
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... 2014 Recently, MyDressCity.com, one of the ... occasion outfits, has released its new range of ... products are available at discounted prices. Worldwide clients can ... , In the company’s online shop, there are plenty ... are made with great materials. MyDressCity.com’s hot items are ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... , NAPA, Calif., Aug. 19 Dey ... today issued an advisory regarding two lots of its Albuterol Sulfate ... that was stolen in McKinney, Texas. , , ... brand name "DEY" and contains thirty 3ml single-dose vials. The lot ...
... , , , ... released the following statement after President Obama said that it,s ... the health care reform plans. , , ... "Tonight, President Obama deliberately misled the American people by ...
... , , , ... one of four companies to have been awarded a contract to ... The contract becomes effective October 1, 2009. , , ... work with the State of Arizona and offer our innovative health ...
... Aug. 19 (HealthDay News) -- People with lung cancer who ... a drug called Tarceva, which is believed to work well ... who take the drug, new research has found. , According ... 20 issue of the New England Journal of Medicine ...
... NEW YORK, Aug. 19 One of the few bright spots of ... and HBA Global Expo ( www.hb a e ... activists to deliver a Keynote Presentations on Tuesday, September 15, 2009 at ... New York. Horst M. Rechelbacher, founder of Intelligent Nutrients and ...
... a novel robot-assisted endoscopic technique, a team of surgeons ... has successfully treated 200 consecutive patients with thyroid cancer. ... cosmetic benefits that the traditional open operation does not ... Journal of the American College of Surgeons . ...
Cached Medicine News:Health News:Dey Issues Advisory 2Health News:President Obama Misleads on Abortion Funding in Health Care Reform 2Health News:CIGNA Awarded State of Arizona Health Care Contract 2Health News:Gene Mutation Improves Response to Lung Cancer Drug 2Health News:Gene Mutation Improves Response to Lung Cancer Drug 3Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 2Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 3Health News:New robot-assisted surgical method found successful for treatment of thyroid cancer 2
... Screening Panel 1 is an enzyme ... detection,of autoantibodies against various specific nuclear ... serum, and is used,as an aid ... erythematosus (SLE), mixed connective tissue disease ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... Concepts manufactures slides that are compatible with ... decrease the number of pipetting steps required ... dilutions on the slides. Ask Immuno Concepts ... these slides. These slide formats are noted ...
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
Medicine Products: